ASCI Perspectives: Jose C. Florez, MD, PhD
DEIC Committee member Dr. Vijay Sankaran interviewed Jose C. Florez, MD, PhD (view profile), who serves as Physician-in-Chief and Chair of the Department of Medicine at Massachusetts General Hospital, Professor of Medicine at Harvard Medical School, and a member of the Broad Institute of MIT and Harvard. Dr. Florez’s lab has conducted and analyzed high-throughput genomic studies in type 2 diabetes. As MGH chair, he oversees numerous faculty members and trainees. In this interview, Dr. Florez discusses how genomic medicine can transform patient care, as well as the importance of being open to change in one’s career.
Uroczysta Inauguracja Roku Akademickiego 2023/2024
“The Practice of Medicine in the 21st Century”
Inaugural Lecture of the Academic Year 2023-2024
Medical University of Bialystok
Massachusetts General Hospital Medical Grand Rounds
“A Vision for the Department of Medicine at MGH”
Jose C. Florez, MD, PhD
Physician-in-Chief and Chair, Department of Medicine, MGH
Investigator, Center for Genomic Medicine, MGH
Institute Member, Broad Institute
Professor of Medicine, Harvard Medical School
New partnership seeks to treat cause of diabetes
The Broad Institute and Novo Nordisk have formed a research partnership.
Tackling Diabetes From Every Angle
Physicians, geneticists, chemists, and other researchers in Broad’s Diabetes Research Group are working together and taking multiple approaches to improve treatment for patients with diabetes.
ADA 2019 – Diabetes Research Across the Spectrum
Jose C Florez joins us at the ADA annual meeting 2019 to discuss his presentation on diabetes research across the spectrum – from cell-based to clinical translation.
Filmed at the American Diabetes Association (ADA) annual meeting 2019, San Francisco, USA
1) What are the major obstacles to achieving personalised medicine in diabetes?
2) What is the role of epigenetic changes in the progression of type 1 and type 2 diabetes?
3) How will increased understanding of these changes affect the management of patients of diabetes?
4) What further research is needed to elucidate the genetic architecture of type 2 diabetes?
5) What recent advances in translational research in diabetes have excited you most?
Highlights of the ADA 79th Scientific Sessions
We take a look at some of the highlights of the last two days of the ADA 79th Scientific Sessions, and who better to take a look at the program with us than ADA Scientific Sessions planning committee chair Dr Jose Florez.
Massive NIH–industry project opens portals to target validation
Five years in, the US$360 million Accelerating Medicines Partnership is yielding tools to speed up drug discovery for rheumatoid arthritis, lupus, diabetes, Alzheimer disease and Parkinson disease.
DNA analysis identifies five subtypes of type two diabetes
The genomic study brings us closer to precision medicine for type 2 diabetes